Annals of Surgical Oncology

, Volume 4, Issue 1, pp 64–69 | Cite as

Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor

  • Annette F. T. Olieman
  • Robert J. van Ginkel
  • Harald J. Hoekstra
  • Eduard L. Mooyaart
  • Willemina M. Molenaar
  • Heimen Schraffordt Koops
Original Articles


Background: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and melphalan is associated with a dramatic anti-tumor effect in which the neo-vascularization of the tumor is supposed to be the major target. The aim of the present study was to correlate the angiographic findings with the pathological response in patients undergoing HILP for locally advanced soft-tissue sarcoma.

Patients and Methods: Twenty-five patients, 14 male and 11 female, mean age 47 years (range 18–80) were studied. Angiographies were performed before and a median period of 7 weeks (range 4–14 weeks) after HILP. Eight weeks after perfusion, the residual tumor mass was resected and pathologically examined. The changes in tumor vascularization after treatment were scored and compared with the pathological response.

Results: All baseline angiograms showed a hypervascular tumor. After HILP, a normal angiography result (NA) was observed in 18 patients (72%) and an abnormal angiography result (AA) was observed in seven patients (28%). All patients with an NA showed a pathologically complete response (pCR) or a pathological partial response with >90% necrosis of the tumor. Of seven patients with an AA, pathological examination showed a pCR in one patient, 10–50% viable tumor volume in four patients, and no pathological response after perfusion in two patients. A good correlation was seen between angiographic and pathological classification (p<0.001).

Conclusion: An angiography performed after hyperthermic isolated limb perfusion with TNF-α and melphalan provides a good indication, regardless of whether a good pathological response is expected.

Key Words

Hyperthermic isolated limb perfusion Angiography Sarcoma Tumor necrosis factor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wingo PA, Tong T, Bolden S. Cancer statistics, 1995.CA 1995;45:8–30.PubMedGoogle Scholar
  2. 2.
    Chang AE, Rosenberg SA. Clinical evaluation and treatment of soft tissue tumors. In: Enzinger FA, Weiss SW, eds.Soft tissue tumors. St. Louis: CV Mosby, 1988:19–42.Google Scholar
  3. 3.
    Hogeboom WR, Hoekstra HJ, Mooyaart EL, Freling NJ, Schraffordt Koops H. MRI and CT in the preoperative evaluation of soft-tissue tumors.Arch Orthop Trauma Surg 1991;110:162–4.PubMedGoogle Scholar
  4. 4.
    Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults.J Clin Oncol 1992;10:1317–29.PubMedGoogle Scholar
  5. 5.
    Mazanet R, Antman KH. Sarcomas of soft tissue and bone.Cancer 1991;68:463–73.PubMedGoogle Scholar
  6. 6.
    Hoekstra HJ, Schraffordt Koops H, Oldhoff J. Soft tissue sarcoma of the extremity.Eur J Surg Oncol 1994;20:3–6.PubMedGoogle Scholar
  7. 7.
    Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.Ann Surg 1958;148:616–32.PubMedGoogle Scholar
  8. 8.
    Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities.Surg Gynecol Obstet 1969;129:305–8.PubMedGoogle Scholar
  9. 9.
    Baas PC, Schraffordt Koops H, Hoekstra HJ, Oosterhuis JW, van der Weele LT, Oldhoff J. Isolated regional perfusion in the treatment of local recurrence, satellitosis and in transit metastasis of the extremities.Reg Cancer Treat 1988;1:33–6.Google Scholar
  10. 10.
    Edwards MJ, Soong SJ, Boddie AW, Balch CM, McBride CM. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone.Arch Surg 1990;125:317–21.PubMedGoogle Scholar
  11. 11.
    Schraffordt Koops H, Kroon BBR, Lejeune FJ. Management of local recurrence, satellites and in transit metastases of the limbs with isolation perfusion. In: Lejeune FJ, Chaudhuri PK, Das Gupta TK, eds. Malignant melanoma: medical and surgical management. New York: McGraw-Hill, 1994:221–31.Google Scholar
  12. 12.
    Guchelaar HJ, Hoekstra HJ, De Vries EGE, Uges DR, Oosterhuis JW, Schraffordt Koops H. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.Br J Cancer 1992;65:898–902.PubMedGoogle Scholar
  13. 13.
    Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion.Ann Surg 1977;185:555–64.PubMedGoogle Scholar
  14. 14.
    Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities.Cancer 1987;60:1703–7.PubMedGoogle Scholar
  15. 15.
    Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.World J Surg 1992;16:227–33.PubMedGoogle Scholar
  16. 16.
    Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.J Clin Oncol 1992;10:52–60.PubMedGoogle Scholar
  17. 17.
    Trojani M, Contesso G, Coindre JM, et al. Soft tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system.Int J Cancer 1984;33:37–42.PubMedGoogle Scholar
  18. 18.
    Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis H. Isolated regional perfusion in malignant melanoma of the extremities.World J Surg 1987;11:527–33.PubMedGoogle Scholar
  19. 19.
    Fontijne WP, Mook PH, Schraffordt Koops H, Oldhoff J, Wildevuur CR. Improved tissue perfusion during pressure regulated regional perfusion: a clinical study.Cancer 1985;55:1455–61.PubMedGoogle Scholar
  20. 20.
    Wieberdink J, Benckhuysen C, Braat RP, Van Slooten EA, Olthuis GAA. Dosimetry in isolation perfusion of the limb by assessment of perfused tissue volume and grading of toxic tissue reactions.Eur J Cancer Clin Oncol 1982;18:905–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Hoekstra HJ, Naujocks T, Schraffordt Koops H, et al. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results.Reg Cancer Treat 1992;4:301–4.Google Scholar
  22. 22.
    Lienard D, Eggermont AM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multicentre pilot study.Melanoma Res 1994;4(suppl 1):21–6.PubMedGoogle Scholar
  23. 23.
    Eggermont AMM, Schraffordt Koops H, Lienard D, van Geel AN, Hoekstra HJ, Lejeune FJ. High dose TNF-alpha in combination with gamma interferon and melphalan in isolated perfusion of the limb for irresectable soft tissue sarcomas: a highly effective approach to achieve limb salvage.J Clin Oncol (in press).Google Scholar
  24. 24.
    Renard N, Lienard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFa).Int J Cancer 1994;57:656–63.PubMedGoogle Scholar
  25. 25.
    Van de Wiel PA, Bloksma N, Kuper CF, Hofhuis FM, Willers JM. Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity.J Pathol 1989;157:65–73.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc 1997

Authors and Affiliations

  • Annette F. T. Olieman
    • 3
  • Robert J. van Ginkel
    • 3
  • Harald J. Hoekstra
    • 3
  • Eduard L. Mooyaart
    • 1
  • Willemina M. Molenaar
    • 2
  • Heimen Schraffordt Koops
    • 3
  1. 1.Department of RadiologyUniversity Hospital GroningenGroningenThe Netherlands
  2. 2.Department PathologyUniversity Hospital GroningenGroningenThe Netherlands
  3. 3.Department of Surgical OncologyUniversity Hospital GroningenGroningenThe Netherlands

Personalised recommendations